About
About AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes; and clinical trial services. The company has a strategic collaboration with Leica Biosystems and Daiichi Sankyo Company, Limited for the development of an immunohistochemistry assay and an image analysis algorithm for the TROP2 NMR biomarker in non-small cell lung cancer. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.
Visit company website
5 years, 4 months ago
AstraZeneca Pharma India Limited is currently in a long term downtrend where the price is trading 8.4% below its 200 day moving average.
From a valuation standpoint, the stock is 121.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 10.6.
AstraZeneca Pharma India Limited's total revenue sank by 10.5% to $2B since the same quarter in the previous year.
Its net income has dropped by 21.2% to $211M since the same quarter in the previous year.
Finally, its free cash flow fell by 98.0% to $13M since the same quarter in the previous year.
Based on the above factors, AstraZeneca Pharma India Limited gets an overall score of 0/5.